About the Event
Evecxia Therapeutics’ lead drug candidate EVX-101 is a potentially superior treatment for the millions of depression patients not treated adequately by standard antidepressants, e.g., Prozac®. Evecxia’s second drug candidate EVX-301 could become the first drug for patients hospitalized for suicidal ideation crisis and a critical tool in reducing lives lost to suicide. Both EVX‑101 and EVX-301 have successfully completed clinical safety trials (“Phase 1”) in healthy volunteers and are ready for proof-of-concept trials (“Phase 2”) in patients. The depression treatment market in 2022 was $12B and is projected to grow to $16B by 2030.
First-line antidepressants, e.g., Prozac®, work well in only one-third of patients. Current next-line antidepressants, e.g., Abilify®, provide only modest additional relief and are saddled with often serious side effects. Data suggest EVX-101 will be safer and more effective than Abilify®, addressing a market of 7 million patients in the U.S. alone. There are 1 million hospitalizations annually in the U.S. for suicidal ideation crisis – but no approved treatments.
Join this Fireside Chat with:
- George Papakostas, MD: Director, Treatment-Resistant Depression Studies, Depression Clinical and Research Program, Massachusetts General Hospital, Professor of Psychiatry, Harvard Medical School
- Jacob Jacobson: Founder and Chief Science Officer, Evecxia Therapeutics
You’ll hear how EVX-101 and EVX-301 could enable many patients suffering from debilitating mood disorders to lead happier and fuller lives.